Los Angeles, CA—ChromaDex Corp. announced in a press release that it has received regulatory authorizations to sell its patented nicotinamide riboside chloride (branded Niagen) to consumers in the European Union and in Australia. As the regulatory applicants and innovators, ChromaDex benefits from market exclusivity in Australia until December 2021 and...
Los Angeles, CA—ChromaDex Corp announced in a press release the initiation of a first-of-its-kind Phase 1 clinical study sponsored by the University of Florida, in collaboration with the National Institute on Aging. The trial will assess the potential of Niagen, ChromaDex’s branded nicotinamide riboside ingredient, to enhance the effects of...
Iowa City, IA--A new animal study from researchers at the University of Iowa found that giving nursing rodents a supplemental form of vitamin B3 (nicotinamide riboside; NR) lead to physical and behavioral benefits for the moms and their babies. In the study, published in Cell Reports, mother mice given NR...
Irvine, CA — Research published in the journal Nature showed promise that nicotinamide riboside (NR) may help lower levels of amyloid deposits and improve mitochondrial energy production and memory in mice with Alzheimer’s Disease. Dr. Johan Auwerx and colleagues at the Ecole Polytechnique Federale de Lausanne in Switzerland conducted a...
